Reagents and instruments for immunology, cell biology and molecular biology.
 
> Mal-Deferoxamine [1638156-31-6]

Mal-Deferoxamine [1638156-31-6]

Print Print
Please log in

Cat# HY-132989-50mg

Size : 50mg

Brand : MedChemExpress

Request more information

Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy..

For research use only. We do not sell to patients.

Mal-Deferoxamine Chemical Structure

Mal-Deferoxamine Chemical Structure

CAS No. : 1638156-31-6

This product is a controlled substance and not for sale in your territory.

Based on 1 publication(s) in Google Scholar

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

View All Isoforms
RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Isoforms
HIF-1α HIF
Description

Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.[1].

IC50 & Target

RDC Bifunctional Chelator

 

Molecular Weight

711.80

Formula

C32H53N7O11
CAS No.

1638156-31-6
Appearance

Solid

Color

White to off-white

SMILES

O=C1C=CC(N1CCC(NCCCCCN(C(CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O)=O)O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 83.33 mg/mL (117.07 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.4049 mL 7.0244 mL 14.0489 mL
5 mM 0.2810 mL 1.4049 mL 2.8098 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: ≥95.0%

SDS (251 KB)

COA (251 KB) HNMR (289 KB) MS (70 KB)

Handling Instructions (2659 KB)
References

  • [1]. Summer D, et al. Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. Mol Pharm. 2018;15(1):175-185.  [Content Brief]

  • [1]. Summer D, et al. Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. Mol Pharm. 2018;15(1):175-185.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.4049 mL 7.0244 mL 14.0489 mL 35.1222 mL
5 mM 0.2810 mL 1.4049 mL 2.8098 mL 7.0244 mL
10 mM 0.1405 mL 0.7024 mL 1.4049 mL 3.5122 mL
15 mM 0.0937 mL 0.4683 mL 0.9366 mL 2.3415 mL
20 mM 0.0702 mL 0.3512 mL 0.7024 mL 1.7561 mL
25 mM 0.0562 mL 0.2810 mL 0.5620 mL 1.4049 mL
30 mM 0.0468 mL 0.2341 mL 0.4683 mL 1.1707 mL
40 mM 0.0351 mL 0.1756 mL 0.3512 mL 0.8781 mL
50 mM 0.0281 mL 0.1405 mL 0.2810 mL 0.7024 mL
60 mM 0.0234 mL 0.1171 mL 0.2341 mL 0.5854 mL
80 mM 0.0176 mL 0.0878 mL 0.1756 mL 0.4390 mL
100 mM 0.0140 mL 0.0702 mL 0.1405 mL 0.3512 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Mal-Deferoxamine Related Classifications

  • Immunology/Inflammation Apoptosis Antibody-drug Conjugate/ADC Related NF-κB PI3K/Akt/mTOR Metabolic Enzyme/Protease Autophagy
  • Akt Autophagy Reactive Oxygen Species Radionuclide-Drug Conjugates (RDCs) HIF/HIF Prolyl-Hydroxylase Apoptosis
Help & FAQs

Keywords:

Mal-Deferoxamine1638156-31-6AktAutophagyReactive Oxygen SpeciesRadionuclide-Drug Conjugates (RDCs)HIF/HIF Prolyl-HydroxylaseApoptosisPKBProtein kinase BHypoxia-inducible factorsHIFsHIF-PHlinkerRDCInhibitorinhibitorinhibit